Leal, formerly known as Trialjectory, has established a predictive patient platform
ArteraAI and the American Cancer Society formed a collaboration focused on the development of AI-driven cancer therapy personalization.
University of Florida Health researchers and Nuance Communications Inc., a Burlington, Massachusetts, firm that specializes in radiology voice recognition and AI deployment, formed a research alliance to develop artificial intelligence tools to make radiologists’ work more precise, safe, and efficient.
Lucem Health established an early disease detection solution, Lucem Health Reveal, which leverages existing EHR data to identify patients who may be at a higher risk of serious or chronic disease.
C2i Genomics entered a collaboration agreement March 2 with Riken Genesis Co., Ltd. to bring MRD cancer monitoring to Japan for pharmaceutical and clinical research.
Utilizing artificial intelligence along with traditional pathology offers promise for swiftly developing treatment plans for patients with non-small cell lung cancers, a team led by UT Southwestern Medical Center researchers discovered.
Scientists at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, collaborating with international researchers, have developed an AI algorithm that performs advanced computational analysis to identify potential therapeutic targets for glioblastoma multiforme and other cancers.
Ibex Medical Analytics entered into an agreement with AstraZeneca and Daiichi Sankyo for the development, clinical validation, and early adoption of an AI-powered product to aid pathologists with an accurate and reproducible assessment of HER2 immunohistochemistry scoring in breast cancer patients.
A study led by investigators from the Mass General Cancer Center, a member of Mass General Brigham, in collaboration with researchers at the Massachusetts Institute of Technology, developed and tested an artificial intelligence tool that accurately predicted the risk of lung cancer for individuals with or without a significant smoking history.
Researchers from Roswell Park Comprehensive Cancer Center and Gero and Genome Protection Inc., recently published new work in Nature Communications in which the artificial neural network applied by the research team precisely projected the health condition of an aging mouse with the help of a single variable, which was termed dynamic frailty indicator (dFI) that accurately characterizes the damage that an animal accumulates throughout life.
